Study Objectives. To assess the use and safety of concurrent administration of voriconazole and sirolimus-which is contraindicated-and to determine approaches for appropriately managing patients who receive both drugs. Design. Retrospective medical record review. Setting. University-affiliated medical center. Patients. Thirty-one cases in 23 inpatients who received at least one dose of voriconazole and sirolimus concomitantly within a 24-hour period. Measurements and Main Results. Data on sirolimus and voriconazole indications, doses, routes, frequencies, and administration times; number of days of coadministration; and sirolimus dosage adjustments were collected. In addition, data on laboratory values, adverse events, sirolimus concentrations, and concomitant drugs, including cytochrome P450 (CYP) 3A isoenzyme and P-glycoprotein inhibitors and inducers, were collected for 7 days before, during, and for 14 days after coadministration. No cases of elevated sirolimus concentrations (> 20 mg/ml) occurred in patients stabilized with voriconazole before starting low-dose sirolimus 0.5-1 mg/day, or in those stabilized with sirolimus 0.5-2 mg/day who had baseline sirolimus concentrations of 12 ng/ml or lower and whose sirolimus dose was decreased by 50% before the addition of voriconazole. In contrast, elevated sirolimus concentrations were experienced in patients receiving sirolimus doses of 4 mg/day or higher who had sirolimus concentrations of 12 ng/ml or higher and whose sirolimus dose was not decreased before addition of voriconazole. In a patient who received sirolimus with itraconazole, a strong CYP3A isoenzyme inhibitor, one case of only a minimal increase in the sirolimus concentration occurred after the addition of voriconazole. Conclusions. Sirolimus and voriconazole can be safely coadministered as long as consideration is given to which agent the patient receives first, the sirolimus dosage, sirolimus concentrations, and concurrent disease states and CYP3A isoenzyme inhibitors. Sirolimus concentrations should be closely and routinely monitored before, during, and after coadministration of voriconazole and other CYP3A isoenzyme inhibitors. Based on the results of this pilot study, a protocol on the management of this drug combination will be implemented and prospectively evaluated for efficacy and safety.
The incidence of invasive fungal infections has increased dramatically in the United States: among infectious diseases-related deaths, those due to invasive fungal infections increased from the tenth most common in 1980 to the seventh most common in 1997. 1 In particular, patients who have undergone solid organ or hematopoietic stem cell transplantation are susceptible to invasive fungal infections because of multiple risk factors, some of which include treatment with immunosuppressive and/or broad-spectrum antimicrobial agents, graft-versus-host disease (GVHD), neutropenia, or the presence of central venous catheters. 2, 3 Invasive fungal infections in transplant recipients are frequently caused by Aspergillus species. Voriconazole, a second-generation triazole antifungal, is often used for prophylaxis or treatment of these infections in transplant recipients as it provides coverage for Candida and Aspergillus species. 2, 4 Voriconazole was shown to be efficacious in noncomparative studies as primary or salvage therapy for invasive fungal infections. [5] [6] [7] Furthermore, it has emerged as the therapy of choice for these infections caused by Aspergillus species, as it demonstrated higher response rates and improved survival compared with amphotericin B in the treatment of invasive aspergillosis. 8 Voriconazole inhibits cytochrome P450 (CYP)-dependent 14␣-lanosterol demethylase, the CYP enzyme responsible for the synthesis of cell membrane ergosterol in fungi. It is both a substrate and an inhibitor of human hepatic CYP2C19, CYP2C9, and CYP3A isoenzymes, increasing the potential for drug interactions with other agents that are substrates of these enzymes, including sirolimus, an antirejection agent used in transplant recipients. 9, 10 Voriconazole drug interactions are dose dependent and are often difficult to predict and manage, in part due to its unpredictable, nonlinear pharmacokinetics and the variability in its concentrations due to genetic polymorphisms of CYP2C19. 10 Sirolimus is an immunosuppressive agent that prevents T-lymphocyte activation and proliferation and antibody production. Unlike tacrolimus and cyclosporine, it does not inhibit calcineurin activity but works by inhibiting the activation of the mammalian target of rapamycin. It is indicated for the prophylaxis of organ rejection in patients receiving kidney transplants; however, it has also been used for the prevention or treatment of rejection in other solid organ transplant recipients and GVHD in hematopoietic stem cell transplant recipients. [11] [12] [13] [14] [15] Concomitant use of voriconazole with sirolimus is contraindicated by the manufacturer 9 because voriconazole inhibits CYP3A isoenzymes, the enzymes responsible for metabolizing sirolimus, resulting in greater susceptibility to dose-related adverse effects of sirolimus, including renal dysfunction, leukopenia, thrombocytopenia, and anemia. 11 Repeated doses of oral voriconazole 400 mg every 12 hours for 1 day, then 200 mg every 12 hours for 8 days administered to 15 healthy young men increased the mean maximum plasma concentration and area under the plasma concentration-time curve of a single, oral 2-mg dose of sirolimus by 7-and 11-fold, respectively. 9 Drug interactions between azole antifungals, such as voriconazole, itraconazole, ketoconazole, or fluconazole, and immunosuppressive agents, including sirolimus, have been extensively reported in the literature. 10, [16] [17] [18] [19] Although the onset and duration of voriconazole-mediated inhibition of CYP3A isoenzymes is unknown, in studies evaluating other CYP inhibitors, inhibition occurred immediately after administration of the first dose of the CYP inhibitor. 20 The duration of CYP3A isoenzyme inhibition after voriconazole administration is believed to be affected by its half-life, which is variable and dose dependent, and by protein binding. 9, 20 At our institution, we noted that increasing numbers of patients were receiving the combination of voriconazole and sirolimus. As only very limited data were available regarding the concurrent use of these two agents, and we found no data regarding the management of patients receiving voriconazole before the start of sirolimus, we evaluated all patients treated at our institution in whom both drugs were coadministered. The objective of this retrospective study was to assess the use of concurrent administration of voriconazole and sirolimus, and to determine approaches for appropriately managing patients who receive both drugs. In addition, the safety of concurrent administration of voriconazole and sirolimus was assessed by determining whether clinicians prospectively or concurrently adjusted sirolimus doses, and by evaluating whether patients experienced increased adverse events due to elevated sirolimus concentrations after coadministration with voriconazole.
Methods
In this retrospective study, we reviewed the medical records of inpatients who were on a medical service at the University of Michigan Hospital who received coadministration of sirolimus and voriconazole between July 1, 2002, and November 1, 2006. Institutional review board approval was obtained, and informed consent was waived as the study did not involve any direct patient interventions. Patients were included if they were inpatients at the University of Michigan Hospital and had received at least one dose of voriconazole and sirolimus concurrently within a 24-hour period. Patients were excluded if their medical records were unavailable for review or were incomplete. Each patient was assigned a case number, and if the patient was admitted more than one time and received coadministration of the two drugs, the original case number followed by a decimal was used to indicate subsequent admissions (e.g., case 2.2 refers to the second admission for the patient assigned case number 2).
Computerized pharmacy and medical databases were used to identify inpatients at the hospital who had drug orders for voriconazole and sirolimus on the same days. Medical records and medication administration records were then reviewed to confirm the specific doses and administration times of all drugs.
Demographic data were collected, including patients' age, sex, race-ethnicity, type of transplantation, and other comorbidities. The following information was collected 7 days before, during, and 14 days after coadminis-tration of sirolimus and voriconazole: indication for sirolimus and voriconazole based on physician progress notes; dose, route, frequency, and administration times for sirolimus and voriconazole; sirolimus concentrations and time of sample collection; dose, route, frequency, and administration times for other concomitant drugs that had potential to affect the drug interaction; laboratory values; and adverse effects. Data on 30-day mortality after the last day of combination therapy as an inpatient were also collected. The definitions of adverse effects relative to baseline laboratory values are listed in Table 1 . Data on rash, neurotoxicity, and death were also assessed.
Sirolimus concentrations were measured by the liquid chromatography with mass spectrometry (LCMS) method; a trough concentration of 5-20 ng/ml was considered therapeutic. [21] [22] [23] In this study, concentrations greater than 20 ng/ml were considered elevated based on current clinical practice in our institution and literature citing target trough ranges of 12-20 ng/ml (using the LCMS methodology) after cyclosporine withdrawal in renal transplant recipients. 22 clinical pharmacists on each service interpret the concentrations based on the timing and estimate trough concentrations accordingly.
Results
Of 31 patients who had orders for voriconazole and sirolimus on the same day, there were 43 separate cases. After reviewing the medication administration records, 12 cases (in 8 patients) were excluded because the patients had not actually received the agents concomitantly within a 24-hour period. This left 31 cases (in 23 patients) of coadministration of voriconazole and sirolimus for inclusion in the study. In 13 (46.4%) of 28 cases, the patients were discharged from the hospital with the combination of sirolimus and voriconazole. The remaining 3 cases were in patients who died while in the hospital.
Of the 23 patients, seven had undergone solid organ transplantation and 16 had received a hematopoietic stem cell transplant ( Table 2) . Coadministration of voriconazole and sirolimus occurred for a mean of 4.6 ± 4.2 days and ranged from 1-20 days (Table 3) . Three types of case scenarios were identified: in 9 cases (9 patients), voriconazole was administered before the addition of sirolimus; in 13 cases (13 patients), sirolimus was administered before the addition of voriconazole; and in 9 cases (4 patients), patients were receiving the two agents concurrently on admission to the hospital. Overall, sirolimus concentrations were obtained during the admission in 30 (97%) of the 31 cases (Table 4) .
Voriconazole Administration Before the Addition of Sirolimus
In this scenario, sirolimus concentrations were obtained during the period of sirolimus coadministration with voriconazole in 7 (78%) of the 9 cases (Table 5 ); however, in 2 patients (cases 11 and 23), no sirolimus concentrations were obtained during coadministration. In these 7 cases, the first sirolimus concentration obtained during coadministration was a mean ± SD of 14.8 ± 11.8 ng/ml (range 3.4-36.0 ng/ml) and was obtained 35.1 ± 24.6 hours (range 6-71 hrs) after the start of coadministration. In the 4 cases (1, 3, 7, and 14) in which the initial sirolimus dose was low (0.5-1 mg/day) and in case 20 in which a 6-mg loading dose was given, subsequent sirolimus concentrations were less than 20 ng/ml. In contrast, in 2 cases (2 and 8) in which 12-and 4-mg, respectively, loading doses were given, the patients experienced elevated (> 20 ng/ml) sirolimus concentrations of 24.9 and 36.0 ng/ml, respectively (Table 5 ). Figure 1 depicts the concentrations of sirolimus in case 8: this patient was receiving voriconazole before administration of a 4-mg loading dose of sirolimus; subsequent sirolimus concentrations were greater than 20 ng/ml.
Sirolimus Administration Before the Addition of Voriconazole
Sirolimus concentrations were obtained both before and during coadministration with voriconazole in 10 of the 13 cases in this scenario (Table 6 ); however, in 3 patients (cases 13, 16, and 19) no sirolimus concentrations were obtained after the addition of voriconazole. In these 10 cases, the mean ± SD baseline sirolimus concentration was 11.4 ± 8.2 ng/ml (range 3.4-30.8 ng/ml), which was obtained 99.7 ± 114.1 hours (range 2-384 hrs) before the addition of voriconazole. The first sirolimus concentration and its time obtained after addition of voriconazole were 15.7 ± 12.9 ng/ml (range 2.8-39.6 ng/ml) and 37.7 ± 40.3 hours (range 0.5-141 hrs), respectively. In 7 cases in which the patients received sirolimus doses of 0.5-2 mg/day and whose sirolimus concentrations before adding voriconazole ranged from 3.4-13.2 ng/ml, sirolimus concentrations were less than 20 ng/ml after adding voriconazole (Table 6) .
Dramatically elevated sirolimus concentrations (> 20 ng/ml) occurred in 3 cases in this scenario. In case 6, the patient received sirolimus 6 mg/day as an outpatient and had a sirolimus concentration of 12.5 ng/ml 68 hours before the addition of voriconazole. The subsequent sirolimus concentration at hour 102.5 (26 hrs after coadministration) was 32.7 ng/ml (Figure 2) . In case 12, the patient received sirolimus 2 mg/day on admission, but the dose was increased to 4 mg/day on the second day of admission; 24 hours after the dose increase the sirolimus concentration was 17.6 ng/ml. Despite a 50% decrease in the sirolimus dose after voriconazole was added, a sirolimus concentration of 27.6 ng/ml was observed 56 hours after the start of coadministration. In case 21, the patient received sirolimus 1 mg every 12 hours in combination with oral itraconazole 200 mg/day (a strong CYP3A isoenzyme inhibitor), thus the patient experienced elevated sirolimus concentrations (30.8-56.0 ng/ml) before coadministration of sirolimus and voriconazole. The total daily dose of sirolimus was reduced by 50% and the sirolimus concentration decreased to 30.8 ng/ml before coadministration of voriconazole and sirolimus. Only a minimal increase in sirolimus concentrations to 39.6 ng/ml was observed with addition of voriconazole (Figure 3 ).
Voriconazole and Sirolimus Already Being Received Concurrently on Admission
In 9 cases (in 4 patients), patients were already receiving the combination of voriconazole and sirolimus on admission. Combination therapy was also started as inpatients in cases 5, 7, and 14, whereas in case 9 it had been started only as an outpatient. In case 5, the patient received the combination for approximately 1 year (the patient was admitted 5 times during a 1-yr period); sirolimus concentrations were successfully maintained at less than 20 ng/ml (mean sirolimus concentration of 7.8 ± 1.8; range 3.6-9.4 ng/ml) throughout this period with a regimen of oral sirolimus 1 mg/day and voriconazole 200 mg every 12 hrs.
Concurrent Use of Cytochrome P450 3A Isoenzyme or P-glycoprotein Inducers or Inhibitors
In 2 cases, the patients were concurrently receiving a CYP3A isoenzyme inducer before and during coadministration of voriconazole and sirolimus (Tables 5 and 6 ). In no cases did the patients receive a concomitant P-glycoprotein inducer, but in 9 cases the patients received a Pglycoprotein inhibitor (itraconazole, cyclosporine, or omeprazole 10, 24 ) during coadministration.
Adverse Effects of Combination Therapy
Adverse effects potentially attributable to elevated sirolimus concentrations (> 20 ng/ml) occurred in 2 (8%) of 25 cases; sirolimus concentrations were not available in 6 cases. In case 2, the patient developed thrombocytopenia with no other identifiable causes. In case 8, the patient developed renal dysfunction requiring hemodialysis and leukopenia, although tacrolimus may have contributed to these toxicities; however, the patient's tacrolimus concentrations were within normal limits (4-6.7 ng/ml).
The 30-day mortality rate after the last day of combination therapy as an inpatient was 30% (7 of 23 patients). Six (86%) of these seven patients were not receiving combination therapy at the time of death. The causes of death were infectious complications in three patients and transplant complications in four patients.
Discussion
Although the voriconazole prescribing information states that its use with sirolimus is contraindicated, 9 clinicians have been faced with the challenge of still needing to use the two agents together. Despite a lack of prospective, randomized, controlled studies evaluating the concurrent use of voriconazole and sirolimus in the transplant population, several published case reports describe the concomitant use of these two agents. In one case report, in which a patient received sirolimus 1 mg/day while receiving voriconazole, the area under the plasma concentration-time curve of sirolimus increased by 4.5-fold during concurrent administration with voriconazole; on discontinuation of voriconazole, the sirolimus dose had to be increased to 3 mg/day to maintain therapeutic sirolimus concentrations. 17 This report also described increased sirolimus concentrations when voriconazole was administered concomitantly in two other transplant recipients. The sirolimus concentration increased by 2.5-fold when a patient, who had been stabilized with sirolimus 4 mg/day, began to receive voriconazole despite a slow taper of the sirolimus dose to 1 mg/day. The other patient had been maintained with sirolimus 1.5 mg/day (concentrations ranged from 17-19 ng/ml before the addition of voriconazole), and the concentration (sirolimus was continued at 1.5 mg/day) increased to 29 ng/ml 2 weeks after the addition of voriconazole.
A second case report noted that in two patients treated with voriconazole and sirolimus concurrently, the sirolimus dose had to be decreased by 75-87.5% in order to maintain therapeutic trough concentrations of sirolimus. 18 A case series reviewed 11 patients who received the two agents together for a median of 33 days (range 3-100 days). 16 In the 8 patients whose sirolimus dose was decreased by 90% after the addition of voriconazole, no toxicity was observed, and sirolimus trough concentrations remained within 3-12 ng/ml, the target trough range in that study. The three patients who did not have their sirolimus doses reduced when voriconazole was added had sirolimus trough concentrations above the upper limit of the target trough range; however, it was not reported whether these patients were also receiving other CYP3A isoenzyme inhibitors during that time. To coadminister these two agents safely, consideration must be given to which agent (sirolimus or voriconazole) the patient is receiving first, the dosage of sirolimus, the sirolimus concentration before the addition of voriconazole if the patient is already receiving sirolimus, and concurrent CYP3A isoenzyme inhibitors or inducers. As illustrated by our cases 2 and 8 and the drug interaction study in healthy subjects reported in the voriconazole package insert, 9 large loading doses of sirolimus are generally not necessary in patients who have been receiving voriconazole before the addition of sirolimus. The CYP3A isoenzyme activity of patients receiving voriconazole will be inhibited already, and thus, they will have lower amounts of active enzyme to metabolize sirolimus. As illustrated in cases 1, 3, 7, and 14, these patients should begin to receive sirolimus at lower doses (0.5-1 mg/day) and sirolimus concentrations should be monitored closely.
In patients receiving sirolimus before the addition of voriconazole, the management strategy should be based on the daily dose of sirolimus, the sirolimus concentration before addition of voriconazole, and whether the patient has been receiving other CYP3A isoenzyme inhibitors. Patients stabilized with low doses of sirolimus (0.5-2 mg/day) and with prevoriconazole sirolimus concentrations of 12 ng/ml or lower may need only a 50% decrease in their sirolimus dose before addition of voriconazole, as demon- 10-12 These patients may have higher amounts of baseline CYP3A isoenzymes (perhaps due to the presence of CYP3A inducers, such as rifampin, phenytoin, or phenobarbital) and thus need higher doses of sirolimus to reach target sirolimus concentrations. Inhibition of CYP3A isoenzymes in these patients may cause a significant decrease in the amount of active CYP3A isoenzymes, inhibiting the metabolism of sirolimus and resulting in significant elevations in sirolimus concentrations.
Patients receiving other CYP3A isoenzyme inhibitors concurrently with sirolimus, as in case 21 who had been receiving itraconazole, may only need minor sirolimus dosage adjustments with the addition of or change to another CYP3A isoenzyme inhibitor. Adding another CYP3A isoenzyme inhibitor or changing to another agent with a similar degree of CYP3A isoenzyme inhibition will likely cause very little change in CYP3A isoenzyme activity because the patient's enzyme activity may be maximally inhibited by the first inhibitor.
It is important for clinicians to remember that the duration of enzyme inhibition produced (and thus the effect on substrate concentrations) may be quite prolonged, in particular if both the substrate and the inhibitor have long half-lives. This can be readily observed in case 6 (Figure 2) , where administration of only two doses of voriconazole resulted in prolonged inhibition of sirolimus.
Nevertheless, sirolimus concentrations should be monitored routinely during coadministration with voriconazole and when any other CYP3A isoenzyme inhibitors are added to or deleted from the patient's drug regimen, as not all interactions are predictable. For example, the patient in case 20, who had been receiving voriconazole, did not experience as elevated a sirolimus concentration as expected after administration of a loading dose of sirolimus of 6 mg; the measured concentration was 15.1 ng/ml after coadministration. The patients in cases 17 and 22 had to have their sirolimus doses increased, despite the addition of voriconazole, to maintain therapeutic sirolimus concentrations. These patients may not have been fully absorbing the voriconazole or sirolimus (case 17 had GVHD of the gastrointestinal tract, case 20 had been receiving total parenteral nutrition, and case 22 had cystic fibrosis) or may have had altered voriconazole metabolism (as described below). Case 15 had a sirolimus concentration of 13.2 ng/ml before and after the addition of voriconazole. The postvoriconazole concentration was obtained 0.5 hour after the dose of sirolimus was given; thus, the patient may not have fully absorbed the sirolimus as the time to peak sirolimus absorption is 1-2 hours, and this patient also had GVHD of the gastrointestinal tract.
Plasma voriconazole concentrations are unpredictable due to inconsistent absorption and genetic polymorphisms in CYP2C19, the isoenzyme primarily responsible for voriconazole' s metabolism. Variations in plasma voriconazole concentrations may in turn affect its degree of CYP3A isoenzyme inhibition, resulting in inconsistencies in sirolimus concentrations. Furthermore, whether sirolimus, a weak CYP3A isoenzyme inhibitor, affects voriconazole concentrations is not known. Voriconazole concentrations were not monitored in our study patients. However, we recognize that measuring voriconazole concentrations would be helpful in future studies assessing the drug interaction between these two agents.
Several limitations must be considered when evaluating this study. As it is a retrospective study based on medical record reviews, we could only report data that had been documented in the patients' medical records, and we did not have access to patients' outpatient medical records. Although we collected data on other CYP3A isoenzymes and P-glycoprotein inhibitors and inducers that the patients received, we were not able to fully characterize the cumulative effects of these inhibitors and inducers on sirolimus concentrations. Target sirolimus concentrations range depending on what type of transplantation the patient receives, the other immunosuppressive agents the patient is receiving concurrently, and how much time has elapsed since the transplantation. The use of other ranges would affect the need for and amount of dosage adjustments. The average turnaround time for sirolimus concentrations at our institution is 1-2 days. Other hospitals may have to send patient samples to another institution for analysis, resulting in a turnaround time of more than 1 week, hindering therapeutic drug monitoring of sirolimus. Finally, the study was limited in terms of the number of patients receiving voriconazole and sirolimus concurrently. Nevertheless, the number of patients in our study is far greater than has been previously reported in the literature.
Conclusion
We evaluated 31 cases (in 23 patients) of voriconazole and sirolimus coadministration. There were only 2 cases in which adverse effects occurred, possibly attributable to elevated sirolimus concentrations. Based on the results of this study and previous literature, the drug interaction between voriconazole and sirolimus is clinically manageable despite the significant CYP3A isoenzyme drug interaction with the potential for elevated sirolimus concentrations. Based on the results of this pilot study, a protocol on the management of the combination of sirolimus and voriconazole will be implemented and prospectively evaluated for efficacy and safety.
